Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 25

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 remaining service period of 0.8 years.

The
Company’s 2023 NeuroNos Ltd. Equity Incentive Plan (the “2023 NNOS Plan”) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of NeuroNos Ltd.’s common stock. The
vesting terms of the options issued under the 2025 NNOS Plan are generally four years and they expire ten years from the grant date.
On September 15, 2025, the Company’s Board of Directors approved to reserve for issuance 1,725,000 shares of common stock. As of
September 30, 2025, 332,861 shares were available under the 2023 NNOS Plan.

A
summary of the change in stock options for NeuroNos for the six months ended September 30, 2025 is as follows:

SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS 

    Number
                                            of Options  
    Weighted Average Exercise Price
                                            of Options  
    Weighted Average Remaining Contractual Life
                                            of Options  
    Aggregate Intrinsic Value (thousands) 

    Options outstanding as of March 31, 2025 
     1,224,139  
    $0.14  
     9.0  
    $3,501 
  
    Granted 
     169,913  
     3.00  
     -  
     - 
  
    Exercised 
     -  
     -  
     -  
     - 
  
    Forfeited 
     (1,913) 
     0.14  
     -  
     - 
  
    Outstanding as of September 30, 2025 
     1,392,139  
    $0.49  
     8.7  
    $3,496 
  
    Exercisable as of September 30, 2025 
     306,035  
    $0.14  
     8.6  
    $875 

As
of September 30, 2025, the Company had unrecognized stock-based compensation expense for the stock options in the 2023 NNOS Plan of approximately
$0.3 million, which is expected to be expensed over the weighted average remaining service period of 1.5 years.

For